How to analyze the company?LEARNWhat should you know before buying?
Get a brief AI stock analysisSaves ~ 15 minutes of your time

OP

NASDAQ:OPTN
Get a brief AI stock analysisSaves ~ 15 minutes of your time

OP

OptiNose IncNASDAQ OPTN Stock Report

Get a brief AI stock analysis
Saves ~ 15 minutes of your time

Price

Market cap $B

Exchange

XNAS - Nasdaq

FAIR VALUE

Is OPTN undervalued compared to its fair value?

The fair value of OPTN stock is hidden USD. Relative to the market price of 1.02 USD OptiNose Inc is hidden.

OptiNose, Inc. operates as a pharmaceutical company. The company is headquartered in Yardley, Pennsylvania and currently employs 141 full-time employees. The company went IPO on 2017-10-13. Its first commercial product, ...[More about valuation]

OptiNose Fair Value

Available for registered user
UNLOCK
What is fair value?

Market cap:

0.148 $B

Price:

1.02 USD

Fair value:

hidden

Max value:

hidden

Min value:

hidden

P/E:

hidden

EPS:

-0.125

FINANCIALS

OptiNose financial for reporting period

Income Statement

0.015 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.0081 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.014 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
Revenue analysis

0.015 B 100%
0.014 B 92%
-0.0081 B -54%
-0.014 B -95%

Balance Sheet

0.084 B
-0.099 B


Financial Position Analysis

Assets

0.084 B
Current Assets
0.081 B
Total non-current assets
0.0026 B

Total current liabilities
0.033 B
Total non-current liabilities
0.15 B

Cash Flow Statement

-0.022 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.022 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

OptiNose fundamental analysis for trailing twelve months (TTM)

Profitability Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Solvency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Efficiency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%
-31 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Dupont Analysis

Stability Indicators

STOCK ANALYSIS

OptiNose Rating

Is OPTN attractive for investment based on fundamental analysis?

OPTN stock rating is hidden. OptiNose is a hidden by Eyestock methodology.

Get OPTN Stock Rating
to complete you analysis
UNLOCK
Learn more about quality score?

Net Profit Margin:

-42

Gross Margin:

89

CFO / Debt ratio:

hidden

Current ratio:

0.723

Debt / Equity ratio:

ROE:

ROIC:

hidden

Stability Ratio (2y):

hidden

Stability Ratio (5y):

hidden

Earnings quality:

hidden

OPTN analysis by AI

Eyebot AI analysis

We carefully consider 10 indicators for OPTN to calculate the final rating score. Use AI leverage to quickly get the main conclusions before diving into the details

OptiNose Inc dividends

OPTN dividend metrics

Payout ratio
Dividend yield
Annual dividend
Dividend streak
Average dividend yield over 3 years
Average dividend yield over 5 years

Dividend per share

By years
By payments
1y
3y
5y
All time
This ticker has no dividend history

About OPTN stock

About the company OptiNose Inc

Market cap $B

0.148

Dividend yield

Shares outstanding

111.81 B

OptiNose, Inc. operates as a pharmaceutical company. The company is headquartered in Yardley, Pennsylvania and currently employs 141 full-time employees. The company went IPO on 2017-10-13. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram, is a therapeutic utilizing its exhalation Delivery System (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. XHANCE combines the EDS with a liquid formulation of fluticasone propionate, a corticosteroid. XHANCE is designed to deliver medication into the high and deep regions of the nasal passages where both nasal polyps and inflamed and swollen membranes can obstruct normal sinus ventilation and drainage. Its powder EDS, which is the EDS used in its ONZETRA Xsail consists of a reusable device body incorporating a flexible mouthpiece to adjust to individual anatomic variations, and a white button piercing assembly to pierce the medication capsule.

OPTN profile

  • Ticker

    OPTN

  • Country

    USA

  • Exchange

    XNAS - Nasdaq

  • Report currency

    USD - US dollar

  • IPO date

    13 October 2017

  • Sector

    Healthсare

  • Industry

    Pharmaceuticals

  • Employees

    141

  • City

    Yardley

  • Address

    1020 Stony Hill Rd Ste 300

  • Cusip

    68404V100

Frequently Asked Questions

What sector does OptiNose operate in?

OptiNose operates in Healthсare sector

What is market cap of OptiNose?

Market cap of OptiNose is 0.148 USD as of 24 Jul 2024

What is market price of one OPTN stock?

Market price of one OPTN stock is 1.02 USD as of 24 Jul 2024

What is OptiNose revenue?

According to the recent report OptiNose revenue is 14.88

What is OptiNose net income?

According to the recent report OptiNose net icnome is -14.067

What is OptiNose net income growh rate?

Net income growth rate of OptiNose is 26